Baccatin III

Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment[1][2].

Product Specifications

CAS Number

[27548-93-2]

UNSPSC

12352005

Hazard Statement

H315, H319, H335, H340, H350

Target

Others

Type

Natural Products

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/baccatin-iii.html

Purity

99.99

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

O=C1[C@H](OC(C)=O)C(C2(C)C)=C(C)[C@@H](O)C[C@@]2(O)[C@@H](OC(C3=CC=CC=C3)=O)[C@@]4([H])[C@@]1(C)[C@@H](O)C[C@@]5([H])OC[C@]54OC(C)=O

Molecular Formula

C31H38O11

Molecular Weight

586.63

Precautions

H315, H319, H335, H340, H350

References & Citations

[1]Lee YH, et al. Baccatin III, a precursor for the semisynthesis of paclitaxel, inhibits the accumulation and suppressive activity of myeloid-derived suppressor cells in tumor-bearing mice. Int Immunopharmacol. 2014 Aug;21 (2) :487-93.|[2]Nie Y, et al. Baccatin III ameliorates bleomycin-induced pulmonary fibrosis via suppression of TGF-β1 production and TGF-β1-induced fibroblast differentiation. Int Immunopharmacol. 2019 Sep;74:105696.